Samsung BioLogics Signs a Strategic Manufacturing Partnership with Roche
Samsung BioLogics today announced that Samsung BioLogics and F. Hoffmann-La Roche have entered into a long term strategic manufacturing agreement under which Samsung will manufacture Roche's proprietary commercial biologic medicines at its two manufacturing facilities in Incheon, South Korea, of which one is currently under construction.
Terms of the agreement will not be disclosed, including financial terms and products to be manufactured. "We are pleased to announce this strategic manufacturing relationship with Roche and look forward to delivering best-in-class manufacturing services with the highest global quality standards," said Tae-Han Kim, president and CEO of Samsung BioLogics. "This collaboration with the world's largest biotech company is an important milestone for Samsung as it validates our long term strategy of becoming a leader in biopharmaceutical manufacturing."
About Samsung BioLogics
Samsung BioLogics is a full-service provider of quality-driven contract process development and cGMP manufacturing to the global biopharmaceutical industry. Our facilities are custom designed for monoclonal antibody & recombinant protein production with maximum flexibility. Our one-stop services include cell line generation, process and analytical method development, analytical services, clinical and commercial bulk cGMP manufacturing of drug substance and drug product meeting the highest standards of quality and global regulatory compliance. For additional information about the company, please visit http://www.samsungbiologics.com.
23.10.2013
